THANK YOU FOR SUBSCRIBING
Angie You, Ph.D., Chief Executive Officer at Amunix, said, "The completion of our Series A financing marks a critical milestone for Amunix, as the investment affords us a significant financial runway to advance our novel pipeline of T cell engagers and cytokines targeting a spectrum of solid tumors. Biologic immune activators hold tremendous untapped promise to help many cancer patients achieve better outcomes"
FREMONT, CA: Amunix Pharmaceuticals, Inc. (Amunix), a biopharmaceutical company based in Mountain View, CA, secured $73 million in Series A round of financing. The round was led by Boston-based Omega funds, with active participation from existing investor Frazier Healthcare Partners, and new investors Polaris Partners, Redmile Group, Longitude Capital, Casdin Capital, Delian Capital, Two River, and Venrock.
Amunix is aiming at advancing a pipeline of Novel T cell engagers (XPATs) and cytokines (XPACs) that are selectively activated in the tumor microenvironment and are carefully designed to immunogenicity and toxicity challenges common to both therapeutic classes. Both the XPAT and XPAC platforms utilize the company's clinically validated XTEN technology, which has demonstrated low immunogenicity, to generate prodrugs.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Amunix intends to use the capital to further advance its lead development candidate, AMX-818, an XPAT T cell engager targeting HER2+ solid tumors into the clinic, to develop earlier discovery stage XPAT programs, to commence XPAC discovery work. Amunix has plans to relocate to South San Francisco later this year.
With closing of the transaction, Otello Stampacchia, Ph.D., Managing Director and Founder of Omega Funds; David Hirsch, M.D., Ph.D., Managing Director and Founder of Longitude Capital; and James Brush, M.D., Partner at Frazier Healthcare Partners, are expected to join Amunix's Board of Directors, soon.
[vendor_logo_first]Amunix was founded in 2006. Since then, it has operated as a technology licensing company, making agreements with multiple top biopharmaceutical companies to leverage XTENpolypeptide as a mask, enabling localized activation of potent therapies. Pro-XTEN has been clinically validated, with advanced program leveraging the technology currently in a pivotal Phase 3 study for a non-oncology indication. Under the tutelage of Dr. You as CEO, Amunix has focused its internal efforts on advancement of the company's proprietary pipeline and advancement of the XPAT and XPAC platforms.
Angie You, Ph.D., Chief Executive Officer at Amunix, said, "The completion of our Series A financing marks a critical milestone for Amunix, as the investment affords us a significant financial runway to advance our novel pipeline of T cell engagers and cytokines targeting a spectrum of solid tumors. Biologic immune activators hold tremendous untapped promise to help many cancer patients achieve better outcomes. We are focused on making this promise a reality by leveraging our clinically validated prodrug platform to deliver T cell engager and cytokine therapies that combine potency with an augmented safety profile and unique ability to evade an undesirable immune response. Our XPAT T cell engager platform holds the potential to deliver off-the-shelf therapies capable of redirecting T cells in the body to fight solid tumors."
See Also :Top FinTech Solution Companies
More in News